Certainly. Below is a **detailed, structured summary** of the regulation titled:

> **"Fees in Respect of Drugs and Medical Devices Order"**  
> (Issued by the Minister of Health, Ottawa, May 3, 2019)  
> S.C. 2017, c. 20, s. 317; R.S., c. F-27

---

## ğŸ” **Overview of the Regulation**

This regulation establishes and governs the **fees for submissions and authorizations related to drugs, veterinary health products, biocides, and medical devices** under the *Food and Drugs Act* and associated regulations. It also outlines **remission (reduction or exemption) of fees** for qualifying applicantsâ€”particularly small businessesâ€”and includes mechanisms for **annual fee adjustments** based on inflation.

The Order was made pursuant to **sections 30.61(1)a and 30.63(1)a of the Food and Drugs Act**, following consultation with interested parties, and is designed to ensure transparency, fairness, and affordability in the regulatory process.

---

## ğŸ“š Key Definitions

| Term | Definition |
|------|-----------|
| **Entity** | As defined in the Criminal Code (an organization). |
| **Fiscal Year** | - For sections 16, 17, 25, 26, etc.: the fiscal year of the applicant or affiliated entities.<br>- Otherwise: April 1 to March 31. |
| **Performance Standard** | The official document titled *Performance Standards for the Fees in Respect of Drugs and Medical Devices Order*, published on **February 16, 2024**. |
| **Small Business** | A person meeting **either**:<br>1. Total employees (including affiliated entities) < 100; OR<br>2. Total gross revenue (including affiliated entities) between **$30,000 and $5 million** (exclusive). |

> **Affiliation Rules**:  
> - Entities are affiliated if one is a subsidiary of the other, or both are subsidiaries of the same entity, or are controlled by the same entity/individual.  
> - A corporation is "controlled" if more than 50% of its voting power is held by an entity/individual (directly or indirectly).  
> - Non-corporate entities are "controlled" if an entity/individual holds more than 50% of profits or assets.  
> - **Deemed affiliation**: If two corporations exist primarily to qualify for small business fee remission, they are treated as affiliated.

> **Note**: These definitions are critical for determining eligibility for fee remission.

---

## ğŸ¯ Purpose of the Order

1. **Fix Fees** for various regulatory actions, including:
   - Examination of new drug submissions (human/veterinary)
   - Supplements to new/abbreviated drug submissions
   - Establishment licence applications
   - Drug identification number (DIN) applications
   - Veterinary health product notifications
   - Preclinical submissions and experimental studies
   - Biocide market authorization applications
   - Medical device licence applications
   - Amendments to Class II, III, or IV medical device authorizations
   - Right to sell drugs or medical devices

2. **Remit (Reduce) Fees** in whole or part under specific conditions (e.g., small business status, public health emergencies, prior authorizations, etc.)

3. **Exclude Certain Applications** from fees:
   - Publicly funded health care institutions
   - Government branches or provincial agencies
   - Extraordinary use new drug submissions (e.g., public health emergencies)

---

## ğŸš« Exclusions (Fees Do Not Apply)

- **Publicly funded health care institutions** (e.g., hospitals, clinics funded by federal/provincial governments)
- **Government branches or provincial agencies**
- **Drugs under extraordinary use new drug submissions** (e.g., emergency drugs under section C.08.002.01)

> *Note: These exclusions ensure that public health services are not burdened by regulatory fees.*

---

## ğŸ’° Fee Adjustment Mechanism (Inflation-Based)

Starting **April 1, 2021**, all fees are **adjusted annually** on April 1 based on inflation:

### Formula:
> New Fee = (Old Fee) Ã— (1 + CPI change over previous 12 months)  
> â†’ Rounded **up to the nearest dollar**

Where:
- **CPI** = April All-items Consumer Price Index for Canada (published by Statistics Canada under the *Statistics Act*)
- The change is calculated over the **previous fiscal year** (April 1 to March 31)

> Example: If the CPI increased by 3.2%, the fee increases by 3.2%.

> Applies to fees in **Divisions 1 to 5 of Part 2** and **Division 1 of Part 3** of the Order (i.e., most drug and device submissions).

---

## ğŸ“„ Fee Structure (Schedule 1)

The fee amounts are detailed in **Schedule 1**, organized by **submission class** (e.g., new drug, supplement, abbreviated submission) and **fiscal year**.

### Two Scenarios:
1. **Fees in listed fiscal years (columns 3â€“6 of Schedule 1)** â†’ Use the fee amount specified in that column.
2. **Fees in other fiscal years** â†’ Calculate using the inflation formula in subsection 4(2).

> The fee is **paid by the person who files the submission**.

---

## ğŸ“ Payment Timeline (Preliminary Examination)

| Scenario | Payment Trigger |
|--------|----------------|
| **Preliminary examination conducted** | - Full fee paid upon receipt of notice that the submission is **complete and accepted**<br>- 10% fee paid if submission is found to be **incomplete** |
| **No preliminary examination** | Full fee paid upon receipt of notice that the submission has been **received** |

> âš ï¸ **Important**: If the Minister issues a notice in the **following fiscal year**, the fee is still based on the **fiscal year in which the submission was filed**.

---

## ğŸš€ Deferred Payment for Co-Submitted Applications

If a person files:
- A **submission** (e.g., new drug) **and simultaneously** applies for authorization under **section C.07.003** of the *Food and Drug Regulations*,

Then **fee payment is deferred** until:
- A **notice of compliance** is issued under section C.08.004, **or**
- A **drug identification number (DIN)** is assigned under subsection C.01.014.2(1)

> This avoids double charging for overlapping processes.

---

## ğŸ Fee Remissions (Reduced or Full Exemptions)

### 1. **Remission for Small Business Applicants**

Subject to **section 18**, remission is granted if:
- The applicant provides a **form established by the Minister** containing:
  - A statement that the applicant **met the "small business" definition** in the **last completed fiscal year**
  - The following supporting data:
    - List of affiliated entities
    - Start/end dates of fiscal years
    - Number of employees (for applicant and affiliates)
    - Gross revenue (for applicant and affiliates)

> **If the applicant has not completed their first fiscal year**:
> - Must provide a **statement of anticipated compliance** with small business status
> - Projected gross revenue and employee numbers for the first fiscal year

> âœ… **Remission amount**:
> - **50% of the full fee** if the applicant meets all conditions

> ğŸš¨ **Note**: This remission is **not available** if the applicant has previously filed a drug submission or a biocide application under section 27.1.

---

### 2. **Remission for Designated COVID-19 Drugs**

If:
- The applicant filed an application under the **ISAD Interim Order** for a **designated COVID-19 drug** (as defined in section C.08.001.1 before the Agile Licensing amendment)
- And later filed a **submission for that same drug**

Then **full remission** of the fee is granted â€” **provided the applicant has not previously filed a submission** for that drug.

> This supports rapid development of emergency treatments during the pandemic.

---

### 3. **Remission for Patent Authorization**

If the applicant has received an **authorization under section 21.04 of the Patent Act** for the drug, then **full remission** of the fee is granted.

> This incentivizes innovation through patent protection.

---

### 4. **Remission for First-Time Filers (No Prior Submissions)**

If:
- The applicant has **never filed a drug submission** or a biocide application under section 27.1
- And meets the small business criteria

Then **full remission** of the fee is granted.

> This encourages new entrants into the market.

---

## âš ï¸ Exceptions to Fee Application

Fees **do not apply** for:
- Submissions reviewed jointly or in parallel with a **foreign regulatory authority**
- Medical device applications that include **drugs** and are subject to a decision under section 36 or 38 of the *Medical Devices Regulations*
- **Public health emergency drugs** under section C.08.002.01 or supplements under C.08.003(7)

> These exceptions reflect the urgency and public interest in emergency responses.

---

## ğŸ“š Key Provisions Summary Table

| Provision | Key Detail |
|--------|